Prostate-specific membrane antigen (PSMA): current benefits and future value.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Seminars in surgical oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1098-2388(200001/02)18:1<10::AID-SSU3>3.0.CO;2-VPMID 10617892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients

  1999cited by this paper
• Vaccine therapy for prostate cancer.

  1999cited by this paper
• Cancer statistics, 1999

  1999cited by this paper
• Prostate-specific membrane antigen.

  1998cited by this paper
• Method for identifying prostate cells in semen using flow cytometry

  1998cited by this paper
• Prostate-specific membrane antigen

  1998cited by this paper
• Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.

  1998cited by this paper
• ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.

  1998cited by this paper
• Prostate cancer abdominal metastases detected with indium-111 capromab pendetide.

  1998cited by this paper
• The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.

  1998cited by this paper
• Prostate-specific membrane antigen: current and future utility.

  1998cited by this paper
• Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.

  1998cited by this paper
• Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen

  1998cited by this paper
• The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.

  1998cited by this paper
• Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen.

  1998cited by this paper
• Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide

  1998cited by this paper
• Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

  1998cited by this paper
• Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.

  1998cited by this paper
• ProstaScint® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients

  1998cited by this paper
• Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line.

  1998cited by this paper
• Prostate carcinoma incidence and patient mortality

  1997cited by this paper
• Prostate‐specific membrane antigen

  1997cited by this paper
• Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.

  1997cited by this paper
• Comparison of serum PSMA, PSA levels with results of cytogen‐356 ProstaScint® scanning in prostatic cancer patients

  1997cited by this paper
• Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351).

  1997cited by this paper
• Prostate-specific membrane antigen expression in normal and malignant human tissues.

  1997cited by this paper
• Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients

  1997cited by this paper
• The results of prostate carcinoma screening in the U. S. As reflected in the surveillance, epidemiology, and end results program

  1997cited by this paper
• Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.

  1997cited by this paper
• Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.

  1997cited by this paper
• Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation.

  1997cited by this paper
• Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

  1997cited by this paper
• Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy.

  1997cited by this paper
• The Role of Prostate-Specific Antigen in the Management of Prostate Cancer

  1996cited by this paper
• Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.

  1996cited by this paper
• Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

  1996cited by this paper
• Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients.

  1996cited by this paper
• Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation.

  1996cited by this paper
• Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.

  1995cited by this paper
• Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP‐based enzyme‐linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement

  1995cited by this paper
• Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen

  1995cited by this paper
• Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.

  1995cited by this paper
• Original Articles: Prostate Cancer: Variable Histology of Anastomotic Biopsies With Detectable Prostate Specific Antigen After Radical Prostatectomy

  1995cited by this paper
• Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen.

  1995cited by this paper
• Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression.

  1995cited by this paper
• Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent.

  1995cited by this paper
• Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy.

  1995cited by this paper
• Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids

  1995cited by this paper
• Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays.

  1994cited by this paper
• Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356.

  1994cited by this paper
• Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.

  1994cited by this paper
• Western blot assay for prostate‐specific membrane antigen in serum of prostate cancer patients

  1994cited by this paper
• Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site‐specific immunoconjugates

  1993cited by this paper
• Topology of eukaryotic type II membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain.

  1991cited by this paper
• Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)

  1991cited by this paper
• Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer

  1987cited by this paper
• Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

  1987cited by this paper

• A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer

  2022cites this paper
• New approach in determination of urinary diagnostic markers for prostate cancer by MALDI-TOF/MS.

  2022cites this paper
• Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer

  2022cites this paper
• Monoclonal antibody based radiopharmaceuticals for imaging and therapy.

  2021cites this paper
• Diagnostic potential of serum extracellular vesicles expressing prostate-specific membrane antigen in urologic malignancies

  2021cites this paper
• New PET radiopharmaceuticals for cancer imaging

  2021cites this paper
• Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer

  2020cites this paper
• Site specific radiolabelling of biomolecules with [99mTc(CO)3]+ and [188Re(CO)3]+ complexes

  2016cites this paper
• Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm

  2015cites this paper
• Isolation of prostate cancer-related exosomes.

  2014cites this paper
• The C-Terminal Fragment of Prostate-Specific Antigen, a 2331 Da Peptide, as a New Urinary Pathognomonic Biomarker Candidate for Diagnosing Prostate Cancer

  2014cites this paper
• Biomarkers in prostate cancer: new era and prospective

  2014cites this paper
• Prostate Cancer Tumor Markers

  2012cites this paper
• Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics

  2012cites this paper
• chapter 98 Prostate Cancer Tumor Markers

  2012cites this paper
• Development, Molecular Biology, and Physiology of the Prostate

  2012cites this paper
• Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II.

  2012cites this paper
• Biomarkers for the diagnosis of new and recurrent prostate cancer.

  2012cites this paper
• ERG and SIM2 transcription factors in prostate cancer – their role in carcinogenesis and potential clinical utility

  2011cites this paper
• Identification of new urine biomarkers for the detection of prostate cancer

  2011cites this paper
• Prostate cancer.

  2011cites this paper
• Biologie moléculaire de la prostate normale et pathologique

  2011cites this paper
• Biomarkers in Cancer

  2010cites this paper
• Biomarcatori emergenti per la diagnosi e la valutazione prognostica del carcinoma della prostata

  2010cites this paper
• Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.

  2010cites this paper
• Engineered antibody and neuropeptide mediated radionuclide targeting in prostate cancer

  2010cites this paper
• [Biomarkers of prostate cancer. A review].

  2010cites this paper
• Other biomarkers for detecting prostate cancer

  2010cites this paper
• Expression of Immunosuppresive B 7-H 3 Ligandby Hormone-Treated Prostate Cancer Tumors andMetastases

  2009cites this paper
• Role of Imaging in Prostate Cancer.

  2009cites this paper
• Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases

  2009cites this paper
• Molecular Imaging of Prostate Cancer: A Concise Synopsis

  2009cites this paper
• Novel biomarkers for prostate cancer including noncoding transcripts.

  2009cites this paper
• Gene expression in prostate cancer

  2008cites this paper
• Emerging biomarkers for the diagnosis and prognosis of prostate cancer.

  2008cites this paper
• New circulating biomarkers for prostate cancer

  2008cites this paper
• Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma

  2008cites this paper
• Circulating biomarkers for prostate cancer

  2007influential citation
• Molecular Evolution of the Transferrin Receptor/Glutamate Carboxypeptidase II Family

  2006cites this paper
• Chapter 14 – Immunohistology of the Prostate, Bladder, Testis and Kidney

  2006cites this paper
• Update on fused capromab pendetide imaging of prostate cancer.

  2005cites this paper
• Purity for clarity: the need for purification of tumor cells in DNA microarray studies

  2005cites this paper
• Duplex RT-PCR and chemiluminometric hybridization assay for combined screening of the mRNAs of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood

  2005cites this paper
• DETECTION OF PROSTATE SPECIFIC mRNAs IN CIRCULATION AND IN PROSTATIC TISSUE

  2005cites this paper
• Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase

  2005cites this paper
• Molecular Techniques in Cancer Diagnosis and Management

  2004cites this paper
• Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line

  2003cites this paper
• Chapter 58 – Are Vaccinations for Prostate Cancer Realistic?

  2003cites this paper
• Recombinant Glutamate Carboxypeptidase II (Prostate Specific Membrane Antigen—PSMA)—Cellular Localization and Bioactivity Analyses

  2003cites this paper
• Isolation and functional analysis of differentially expressed genes in human prostate cancer

  2003cites this paper
• MHC Expression and Immune Mechanisms in Prostate Cancer

  2003cites this paper
• Screening for prostate cancer with prostate-specific antigen: beware the biases.

  2002cites this paper
• Models for Evaluation of Targeted Therapies of Metastatic Disease

  2002cites this paper
• Molecular detection and characterization of circulating tumor cells and micrometastases in prostatic, urothelial, and renal cell carcinomas.

  2001cites this paper
• Autochthonous mouse models for prostate cancer: past, present and future.

  2001cites this paper
• Design considerations for efficient prostate cancer chemoprevention trials.

  2001cites this paper
• Differential gene expression in prostate cancer : identification of genes expressed in prostate cancer, androgen-dependent and androgen-independent LNCaP cell lines, and characterization of TMPRSS2 expression

  2000cites this paper
• Differential Gene Expression in Prostate Cancer Markku Vaarala Differential Gene Expression in Prostate Cancer

  2000cites this paper
• Prostate cancer: therapeutic patent review

  2000cites this paper
• DIFFERENTIAL GENE EXPRESSION IN PROSTATE

  2000cites this paper
• Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours.

  2000cites this paper
• Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.

  2000cites this paper